(Total Views: 654)
Posted On: 11/13/2024 6:57:19 PM
Post# of 155577
Quote: "The one sticking point is the financials. There should enough money to finish the mssCRC trial and the Alzheimer's pilot study costs us nothing. With results from either the ability for Cytodyn to raise money is immensely improved."
Ohm, I agree 100% with you. I believe Cytodyn has enough $ resources to finish mssCRC trial. Alzheimer's pilot study costs us nothing as you correctly point out other than supplying Leronlimab. Achieving excellent results from either or both opens a lot of doors and should help the share price considerably and future fundraising with better terms.
Cytodyn doesn’t have enough $ resources to finish both mssCRC trial and inflammation study. For that reason, priority should be given imo to using available $ to complete mssCRC trial and obtaining results.
Investors Hangout: https://investorshangout.com/post/view?id=672...z8rVPV1Y1S
Ohm, I agree 100% with you. I believe Cytodyn has enough $ resources to finish mssCRC trial. Alzheimer's pilot study costs us nothing as you correctly point out other than supplying Leronlimab. Achieving excellent results from either or both opens a lot of doors and should help the share price considerably and future fundraising with better terms.
Cytodyn doesn’t have enough $ resources to finish both mssCRC trial and inflammation study. For that reason, priority should be given imo to using available $ to complete mssCRC trial and obtaining results.
Investors Hangout: https://investorshangout.com/post/view?id=672...z8rVPV1Y1S
(7)
(0)
